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Carbapenemase-producing organisms (CPO) are rapidly disseminating worldwide, and 
their presence in tertiary care hospitals poses a significant threat to the management of 
nosocomial infections. There is a need to control CPO, especially in intensive care unit 
(ICU) patients, because these organisms are resistant to most β-lactam antibiotics and are 
easily transmitted. At present, the identification of CPO is time-consuming; hence, this 
study focused on the use of the Xpert CARBA-R assay (Cepheid, USA) to determine intes-
tinal colonization rates of CPO in patients admitted to the ICU of a tertiary care hospital in 
Korea. Forty clinical stool samples were collected and inoculated both in a CARBA-R car-
tridge and in conventional culture plates. The CARBA-R assay required only ~one hour to 
screen CPO, while the time required for conventional culture was over three days. We also 
found that the prevalences of intestinal colonization by carbapenem-resistant organisms 
and Enterobacteriaceae were 17.5% (7 out of 40) and 7.5% (3 out of 40), respectively. 
Among the colonizing strains, three that contained carbapenemase, including Klebsiella 
pneumonia carbapenemase (KPC), and imipenem (IMP) and Verona integron-mediated 
metallo-β-lactamase (VIM) were found. With its convenience, the Xpert CARBA-R assay 
can be included in CPO surveillance strategies.
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A rapid increase in the prevalence of carbapenem-resistant or-
ganisms (CRO) has been reported in Korea, particularly in ter-
tiary care hospitals [1, 2]. Among the different resistance mech-
anisms in CRO, the most important is the production of the car-
bapenemase enzyme. The reason for concern about these car-
bapenemase-producing organisms (CPO), which are a subset 
of CRO, is that these enzymes can induce high levels of resis-
tance to most β-lactam antibiotics, including carbapenems, 
which are the last line of defense in the treatment of gram-neg-
ative Enterobacteriaceae infections. In addition, CPO can spread 
and have been related to outbreaks of carbapenem-resistant 
bacteria in both developed and developing countries [3-8]. In 
Korea, six multidrug-resistant organisms, including CPO, have 
been implicated as the main agents of nosocomial infections 
according to the Korean government. It has been mandated for 
hospitals to report infections by these organisms to the Korean 
Center for Disease Control and Prevention since 2012 (http://
www.cdc.go.kr/CDC/).
The risk factors for infection with multidrug-resistant organ-
isms include a previous invasive procedure, diabetes mellitus, 
solid tumors, tracheostomy, urinary catheter insertions, and re-
ceipt of antipseudomonal penicillin [9]. Because the above fac-
tors are common in intensive care unit (ICU) patients, the detec-
tion of CRO or CPO colonization, which easily leads to true infec-
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tions or to the horizontal transfer of carbapenem resistance de-
terminants to other species [10], is very important for infection 
prevention. According to the study reported in 2012, the preva-
lence of fecal carriage of carbapenem-resistant Enterobacteria-
ceae (CRE) was 0.3%; however, to date, there have been no car-
bapenemase-producing Enterobacteriaceae (CPE) reported in 
the ICUs of Korean tertiary care hospitals [11]. Furthermore, a 
Chinese study in 2012 reported the prevalences of CRE and 
CPE, including Klebsiella pneumonia carbapenemase (KPC)-2, 
imipenem (IMP)-4, and New Delhi metallo-β-lactamase (NDM)-1 
producers, to be 6.6% and 2.6%, respectively [12]. However, 
these previous studies utilized conventional methods, which 
were time-consuming and laborious. Recently, the Xpert CARBA-
R assay (Cepheid, Sunnyvale, CA, USA) has been introduced for 
the detection of CPO from clinical samples. This assay is based 
on a multiplex real-time PCR technique and can detect blaVIM, 
blaIMP, blaNDM, blaKPC, and blaOXA-48-like alleles. However, reports 
on its clinical application have been scarce [13]. Hence, we ap-
plied the CARBA-R assay to determine the colonization rate of 
CPO in ICU patients in a tertiary care hospital in Korea and com-
pared its results with those of conventional culture methods.
From July to August 2013, a total of 102 clinical samples were 
collected from ICU patients. Of these, the samples from patients 
in neonatal ICUs or patients with less than  five-day stay in ICU 
were excluded. Additionally, duplicate samples from the same 
patients were excluded. In total, 40 clinical samples, including 
23 stool samples and 17 rectal swabs, from 40 patients were 
evaluated. One of the rectal swabs was inoculated into the sam-
ple reagent and loaded into the cartridge of the CARBA-R assay 
according to the manufacturer’s instructions, while another swab 
was inoculated in MacConkey broth containing 1 μg/mL merope-
nem (MEM) and incubated for 24 hr. The organisms from the 
broth containing MEM were then sub-cultured on MacConkey 
agar plates, each containing an MEM disk. Colonies growing 
near the MEM disks were sub-cultured on MacConkey agar con-
taining 2 μg/mL MEM to ascertain resistance to carbapenem. 
Species were identified by using Matrix-Assisted Laser Desorp-
tion Ionization–Time-of-Flight Mass Spectrometry (Bruker Dalton-
ics, Bremen, Germany). For carbapenemase screening, a modi-
fied Hodge test using an IMP disk and a double disk synergy 
(DDS) test using aminophenyl boronic acid (APBA) and dipico-
linic acid (DPA) vs. MEM were performed [14]. 
Three out of 40 samples (7.5%) tested positive by the CARBA-
R assay, i.e., they showed one blaVIM-, one blaIMP-, and one 
blaKPC-positive signal, indicating that the prevalence of CPO was 
substantial in these ICU patients (Table 1). By conventional cul-
ture, 16 out of 40 samples showed bacterial growth close to the 
MEM disk on MacConkey agar. Of these, seven isolates (three 
Klebsiella pneumoniae, three Pseudomonas aeruginosa, and 
one Pseudomonas monteilii) were resistant to MEM with a mini-
mum inhibitory concentration (MIC) over 2 μg/mL. Among the 
seven MEM-resistant strains, two K. pneumoniae and three P. 
aeruginosa were isolated from samples that tested negative by 
Xpert CARBA-R assay. For these five strains, the modified Hodge 
test was negative. In addition, enhanced inhibition zones were 
observed around APBA disks but not around DPA disks for four 
strains, and one strain showed no inhibition zone around either 
the APBA and DPA disks. This indicated that over-expression of 
Table 1. Summary of the results showing positivity in CARBA-R assay or conventional culture assay
Case No.
Duration 
(day)
Specimen CARBA-R assay Species of CRO MHT 
Double disk 
potentiation test
Possible mechanism
  5 225 Stool Negative Klebsiella pneumoniae Negative Negative AmpC β-lactamase with porin loss
  7 10 Stool Negative Pseudomonas aeruginosa Negative APBA+ AmpC β-lactamase with porin loss
  9 5 Stool VIM+ Pseudomonas monteilii Negative DPA+ Class B carbapenemase
16 11 Rectal swab IMP+ NT* NT* NT* -
23 29 Rectal swab Negative Klebsiella pneumoniae Negative APBA+ AmpC β-lactamase with porin loss
25 44 Rectal swab Negative Pseudomonas aeruginosa Negative APBA+ AmpC β-lactamase with porin loss
26 20 Rectal swab Negative Pseudomonas aeruginosa Negative APBA+ AmpC β-lactamase with porin loss
33 25 Stool KPC+ Klebsiella pneumoniae Positive APBA+ Class A carbapenemase
*Not tested owing to the lack of bacterial growth after overnight incubation in an enrichment (MacConkey) broth with 1 μg/mL MEM or no MEM-resistant 
colony around the MEM disk on MacConkey agar.
Abbreviations: APBA, aminophenylboronic acid; CCU, coronary care unit; CRO, carbapenem-resistant organism; DPA, dipicolinic acid; ERP, ertapenem; 
ICU, intensive care unit, IMP, imipenem; MEM, meropenem; MHT, modified Hodge test; NCU, neurosurgical care unit; NT, not tested; PCCU, pediatric criti-
cal care unit; VIM, Verona integron-mediated metallo-β-lactamase; KPC, Klebsiella pneumonia carbapenemase.
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Amp-C β-lactamase along with porin loss might be the causes of 
carbapenem resistance in these strains.
One P. monteilii isolate from a blaVIM-positive sample was neg-
ative for the modified Hodge test using an IPM disk but positive 
for the DDS test, indicating the limitations of the modified Hodge 
test in carbapenemase screening owing to its relatively low sen-
sitivity [15-17]. Additionally, no bacterial growth was observed 
from the sample showing a positive signal for blaIMP-, indicating 
that the CARBA-R assay is sensitive enough to detect CPO even 
in a rectal swab sample with a very low bacterial concentration. 
Alternatively, this might indicate a limitation of this study: we fol-
lowed the MEM resistance cut-off value for Enterobacteriaceae 
in the CLSI guidelines [18]; however, this cut-off can cause low 
levels of CPO resistance to be missed. In addition, a recent re-
port showed that the CARBA-R assay does not perform well in 
the detection of OXA-48-producing Escherichia coli [19]. There-
fore, further studies are required to determine the prevalence of 
CPO in specific settings and to determine the accuracy of the 
CARBA-R assay with organisms that exhibit a low level of resis-
tance to carbapenems.
Regarding the turn-around time, while over three days were 
required for the conventional culture, the CARBA-R assay re-
quired only about one hour, including 48 min running time. 
The prevalences of intestinal colonization by CRO and CRE 
were 17.5% and 7.5%, respectively, in the ICUs of a tertiary 
care hospital in Korea, which is higher than those previously re-
ported in similar settings [11, 12]. However, owing to the limited 
number of samples, further study will be needed to determine 
the true prevalence of CPO and CPE in the guts of ICU patients. 
The Xpert CARBA-R assay was found to be an easy-to-use as-
say, considering the labor and processing time required for con-
ventional culture. The Xpert CARBA-R assay t should be ad-
opted for surveillance and the determination of CPO colonization 
rates in clinical settings.
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